These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21463127)

  • 1. NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia.
    Guo D; Teng Q; Ji C
    Leuk Lymphoma; 2011 Jul; 52(7):1200-10. PubMed ID: 21463127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
    Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
    Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit.
    Hagenbeek TJ; Wu X; Choy L; Sanchez-Irizarry C; Seshagiri S; Stinson J; Siebel CW; Spits H
    Cancer Lett; 2014 May; 346(2):237-48. PubMed ID: 24384093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
    Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
    J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
    Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
    Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
    Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
    Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
    Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
    Nozhat Z; Hedayati M
    Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
    Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
    J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
    Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
    Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
    Palomero T; Sulis ML; Cortina M; Real PJ; Barnes K; Ciofani M; Caparros E; Buteau J; Brown K; Perkins SL; Bhagat G; Agarwal AM; Basso G; Castillo M; Nagase S; Cordon-Cardo C; Parsons R; Zúñiga-Pflücker JC; Dominguez M; Ferrando AA
    Nat Med; 2007 Oct; 13(10):1203-10. PubMed ID: 17873882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
    Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
    Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy.
    Martelli AM; Tabellini G; Ricci F; Evangelisti C; Chiarini F; Bortul R; McCubrey JA; Manzoli FA
    Adv Biol Regul; 2012 Jan; 52(1):214-27. PubMed ID: 21983557
    [No Abstract]   [Full Text] [Related]  

  • 16. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.
    You D; Xin J; Volk A; Wei W; Schmidt R; Scurti G; Nand S; Breuer EK; Kuo PC; Breslin P; Kini AR; Nishimura MI; Zeleznik-Le NJ; Zhang J
    Cell Rep; 2015 Mar; 10(12):2055-68. PubMed ID: 25801032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
    Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.
    Silva A; Yunes JA; Cardoso BA; Martins LR; Jotta PY; Abecasis M; Nowill AE; Leslie NR; Cardoso AA; Barata JT
    J Clin Invest; 2008 Nov; 118(11):3762-74. PubMed ID: 18830414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.
    Zuurbier L; Petricoin EF; Vuerhard MJ; Calvert V; Kooi C; Buijs-Gladdines JG; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Pieters R; Meijerink JP
    Haematologica; 2012 Sep; 97(9):1405-13. PubMed ID: 22491738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Notch Signaling Promotes the Adipogenic Differentiation of Mesenchymal Stem Cells Through Autophagy Activation and PTEN-PI3K/AKT/mTOR Pathway.
    Song BQ; Chi Y; Li X; Du WJ; Han ZB; Tian JJ; Li JJ; Chen F; Wu HH; Han LX; Lu SH; Zheng YZ; Han ZC
    Cell Physiol Biochem; 2015; 36(5):1991-2002. PubMed ID: 26202359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.